Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,905
Total Claims
$1.5M
Drug Cost
650
Beneficiaries
$2,365
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 218,535 Nurse Practitioner providers
-50%
Opioid rate vs peers
1.9% vs 3.8% avg
+101%
Cost per patient vs peers
$2,365 vs $1,174 avg
+79%
Brand preference vs peers
15.8% vs 8.9% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
1.9%
Opioid Rate
188
Opioid Claims
$1,073
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,552 claims · $1.3M
Generic: 8,247 claims · $183K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 75 | $122K |
| Fluticasone/Umeclidin/Vilanter | 78 | $109K |
| Dulaglutide | 39 | $87K |
| Insulin Degludec | 24 | $68K |
| Sitagliptin Phosphate | 41 | $65K |
| Semaglutide | 34 | $60K |
| Insulin Glargine,hum.Rec.Anlog | 17 | $51K |
| Apixaban | 48 | $48K |
| Linaclotide | 23 | $36K |
| Liraglutide | 12 | $34K |
| Umeclidinium Brm/Vilanterol Tr | 27 | $30K |
| Insulin Lispro | 20 | $29K |
| Tirzepatide | 18 | $28K |
| Insulin Glargine/Lixisenatide | 18 | $26K |
| Linagliptin | 15 | $22K |
Prescribing Profile
Patient Profile
70
Avg Age
64%
Female
1.26
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About